Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received. Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
Page: 1 2 3 4 Related biology technology :1
|SOURCE Valeant Pharmaceuticals International, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer2
. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones3
. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer4
. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ5
. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 20176
. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-997
. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results8
. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results9
. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals10
. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference11
. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence